{'fraction_non_alphanumeric': 0.03741007194244604, 'fraction_numerical': 0.008633093525179856, 'mean_word_length': 5.757281553398058, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Insulin‐like growth factor‐binding protein‐2 in patients with prostate carcinoma and benign prostatic hyperplasia

OBJECTIVE Insulin‐like growth factor‐binding protein (IGFBP)‐2 is a major prostatic IGFBP and may be involved in regulating prostate growth. Patients with prostate carcinoma (PC) have elevated serum IGFBP‐2 levels which correlate with the specific PC marker, prostate‐specific antigen (PSA). The aims of this study were to investigate whether elevated serum IGFBP‐2 is unique to PC or also occurs in benign prostatic hyperplasia (BPH), to examine the relations among age, PSA and IGFBP‐2 levels, and to examine longitudinal changes in serum IGFBP‐2 with PSA in prostate carcinoma.